We have developed several unique functional antibody antagonists targeting PTH1R, a G-protein-coupled receptor involved in the regulation of calcium metabolism.
These antibodies have shown promising efficacy in in vivo studies and could potentially address high unmet medical needs, including hyperparathyroidisms (PHPT) and humoral hypercalcemia of malignancy (HHM).
Our PTH1R program began as an endocrine program, but its mechanism-of-action may be beneficial to oncology patients suffering from HHM. HHM is present in many advanced cancers and is caused by high serum calcium due to increased levels of the PTH1R ligand PTH-related peptide (PTHrP). Since current HHM treatments often fall short and many cancer patients die from ‘metabolic death’, our PTH1R antibodies could be very beneficial for the treatment of HHM.